TY - JOUR
T1 - Molecular therapies for viral hepatitis
AU - Guha, Chandan
AU - Shah, Shalin J.
AU - Ghosh, Siddhartha S.
AU - Lee, Sung W.
AU - Roy-Chowdhury, Namita
AU - Roy-Chowdhury, Jayanta
N1 - Funding Information:
This work was supported in part by the following National Institutes of Health grants: DK 39137 (to Namita Roy-Chowdhury), DK 46057 (to Jayanta Roy-Chowdhury), 1 RO1 A1 42295 (to Marshall S. Horwitz), the Liver Research Core Center (P30-DK 41296) and the Gene Therapy Core of the Seaver Institute of Human Genetics.
PY - 2003
Y1 - 2003
N2 - Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.
AB - Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.
UR - http://www.scopus.com/inward/record.url?scp=0037258795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037258795&partnerID=8YFLogxK
U2 - 10.2165/00063030-200317020-00001
DO - 10.2165/00063030-200317020-00001
M3 - Review article
C2 - 12641487
AN - SCOPUS:0037258795
SN - 1173-8804
VL - 17
SP - 81
EP - 91
JO - BioDrugs
JF - BioDrugs
IS - 2
ER -